The Johns Hopkins spinout will funnel the cash into developing a class of glutamine antagonist that could help treat cancer.
Dracen Pharmaceuticals, a US-based cancer treatment spinout from Johns Hopkins University, completed a $40m series A round on Thursday that featured spinout-focused investment firm Osage University Partners.
Healthcare-focused investment firm Deerfield Management led the round, which also included venture firm I&I Prague.
Founded in 2016, Dracen builds on research from Johns Hopkins University and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague).
The spinout is developing a class of glutamine antagonist that could…
